Merger Notification - Announcement according to § 10 Cartel Act
Boehringer Ingelheim Venture Fund GmbH; Novo Holdings A/S; HepaRegeniX GmbH
BWB/Z-6589
On 27.05.2024 the Austrian Federal Competition Authority was notified of the following merger:
Planned purchase process
Boehringer Ingelheim Venture Fund GmbH and Novo Holdings A/S each intend to acquire non-controlling minority interests in HepaRegeniX GmbH. After completion of the financing round, Boehringer Ingelheim Venture Fund GmbH will hold 34.4% and Novo Holdings A/S 27.9% of the shares in HepaRegeniX GmbH. The proposed merger relates to the market for drug discovery and early clinical research and development of active ingredients and drug candidates in the field of liver diseases.
M - REAL ESTATE ACTIVITIES
Deadline for bringing in an application pursuant to § 11(1) Cartel Act will end on 24.06.2024.
Entrepreneurs whose legal or economic interests are affected by the merger can bring in a written statement at the Federal Competition Authority or the Federal Cartel Prosecutor within 14 days from publication date.
Note: The intervening party has no right to a certain treatment of the statement and will not gain a party position.
Non-prohibition of the merger
The Federal Competition Authority and the Federal Cartel Prosecutor have not applied for examination of the merger by the Cartel Court. The standstill obligation (§ 17 (1) Cartel Act) ends with effect from 25.06.2024 .